CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

CADTH Pharmaceutical Reviews Update — Issue 14

Last updated: March 4, 2020
Product Line: Pharmaceutical Review Update
Issue: 14
Result type: Report

CADTH Program Updates

Pending Consultation on Aligned CADTH Review Procedures

In Spring 2020, CADTH will be consulting stakeholders on its aligned procedures for its drug reimbursement reviews. The new procedures will cover the CADTH pan-Canadian Oncology Drug Review, Common Drug Review, and Interim Plasma Protein Product Review processes. The Plasma Protein Product Review is a joint initiative with Canadian Blood Services. Details about the consultation will be announced in a future issue of the Pharmaceutical Reviews Update.

2. Revised Procedure for the Sponsor Review of Initial CADTH pCODR Reports

Initial CADTH pCODR reports will now be issued to the sponsor four business days before the target posting date instead of three business days before the target posting date. This revised process is effective for all submissions and resubmissions discussed at or after the March 2020 pERC meeting. There are no changes to the overall timelines for the review, and sponsors will continue to have three business days to review the reports for the purposes of validating the handling of confidential information and identifying any factual errors. This revision has been implemented to provide CADTH staff with additional time to prepare and post the documents following the sponsor’s review.

This revision is reflected in an updated version of the Procedures for the CADTH pan-Canadian Oncology Drug Review.

Previous Procedure

Three business days prior to the posting of the initial recommendation and CADTH reports, the sponsor and/or the manufacturer of the drug under review (if not the sponsor) will be provided with the clinical report and the summary of the economic report to be publicly posted.

Revised Procedure

Four business days before the posting of the initial recommendation document and CADTH reports, the sponsor and/or the manufacturer of the drug under review (if not the sponsor) will be provided with the clinical report and the summary of the economic report to be publicly posted.

3. Updated Procedural Document for CADTH’s Common Drug Review and Interim Plasma Protein Product Review Processes

The Procedures for the CADTH Common Drug Review and Interim Plasma Protein Product Review have been reformatted and updated to correct a minor typographical error in Appendix 5 and to redirect several hyperlinks to alternative locations on the CADTH website. No other changes have been made to the content of the document.